Home » Stocks » EVAX

Evaxion Biotech A/S (EVAX)

Stock Price: $6.63 USD 0.05 (0.76%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $6.50 -0.13 (-1.96%) May 7, 4:00 PM
Market Cap 127.29M
Revenue (ttm) n/a
Net Income (ttm) -15.02M
Shares Out 19.20M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $6.63
Previous Close $6.58
Change ($) 0.05
Change (%) 0.76%
Day's Open 6.61
Day's Range 6.51 - 6.78
Day's Volume 13,970
52-Week Range 5.15 - 10.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

COPENHAGEN, Denmark, April 20, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driv...

2 weeks ago - GlobeNewsWire

COPENHAGEN, Denmark, April 06, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve...

1 month ago - GlobeNewsWire

COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve...

1 month ago - GlobeNewsWire

COPENHAGEN, Denmark, March 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve...

1 month ago - GlobeNewsWire

COPENHAGEN, Denmark, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve ...

2 months ago - GlobeNewsWire

COPENHAGEN, Denmark, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patien...

2 months ago - GlobeNewsWire

About EVAX

Evaxion Biotech is a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. Drug discovery and clinical development using historically prevailing techniques is a long, costly process with a high attrition rate. We believe our proprietary AI-immun... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2021
CEO
Lars Staal Wegner, MD
Employees
35
Stock Exchange
NASDAQ
Ticker Symbol
EVAX
Full Company Profile

Financial Performance

Financial Statements